PharmTech AI Pulse Check panelists explain why attribution, audit trails, and sign-off matter more than AI watermark detection for GxP quality teams.
News|Videos|October 2, 2026
PharmTech AI Pulse Check: Episode 2 - Shadow AI, Trade Secrets, the API Race
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
Advertisement
Advertisement
In the second episode of PharmTech's new biweekly video series, “PharmTech AI Pulse Check,” host Chris Cole, associate editorial director, PharmTech, sits down with three expert co-hosts—Richard Jaenisch, Open Biopharma Research and Training Institute, Florin Muraru, independent regulatory affairs advisor, and Gourav Pandey, R&D quality lead, Takeda—to unpack three fast-moving flashpoints in pharma AI: data governance, the shift toward API-gated scientific literature, and the limits of AI-content detection.
Related to this article
API-gated journals may skew pharma regulatory research as AI agents favor accessible sources, raising citation integrity and pharmacovigilance risks.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
Richard Jaenisch explains what FDA's real-world use case database means for CMC and quality teams navigating NAMs.
Boyang Wang, Immortal Dragons, explains how FDA’s Expedited IND Pilot and research partners could speed serial steps to first-in-human trials compared to China’s 818 Decree.
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
Advertisement
Advertisement